BofA Securities Reiterates Buy Rating on Immunovant (IMVT), PT $49, 'catalyst-rich 1H25'
Tweet Send to a Friend
BofA Securities analyst Jason gerberry reiterated a Buy rating and $49.00 price target on Immunovant (NASDAQ: IMVT)The analyst comments "IMVT’s ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
